Biotherapeutics for cancers and infectious disease using PIKA® immunomodulating technology; influencing innate and adaptive immune responses through TLR3, RIG-I and MDA5 pathways. Products in devt include YS-ON-001 (Ph 1), an IO product targeting solid tumors and new gen of biologics for preventive and therapeutic benefits, incl YS-HBV-001 (Ph 1) and PIKA rabies vaccine (Ph 3), targeting hep B and rabies infections. PC programs incl biologics targeting influenza, herpes zoster, ebola, et al. 2 biologics products on mkt. HQ in Beijing, 640 employees WW.
Biological And Medical Industry Base,Daxing District
NO.9 Tianfu, ,Building10, ROOM 309
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.